Mesenchymal stem cells for clinical application

被引:228
作者
Sensebe, L. [1 ,2 ]
Krampera, M. [3 ]
Schrezenmeier, H. [4 ,5 ]
Bourin, P.
Giordano, R. [6 ]
机构
[1] EFS Etab Francais Sang, GECSoM, Ctr Atlantique, F-37206 Tours 3, France
[2] Univ Tours, EA3855, Tours, France
[3] Univ Verona, Dept Clin & Expt Med, Sect Hematol, I-37100 Verona, Italy
[4] Univ Ulm, Inst Clin Transfus Med & Immunogenet, German Red Cross Blood Serv Baden Wurttemberg Hes, Ulm, Germany
[5] Univ Ulm, Inst Transfus Med, Ulm, Germany
[6] Fdn Osped Maggiore Policlin, Ctr Transfus Med Cellular Therapy & Cryobiol, Cell Factory F Calori, Milan, Italy
关键词
Mesenchymal Stem; Stromal Cells; immune intervention; regenerative medicine; GMP; MARROW STROMAL CELLS; VERSUS-HOST-DISEASE; HEMATOLOGIC MALIGNANCY PATIENTS; UMBILICAL-CORD BLOOD; HUMAN ADIPOSE-TISSUE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SUPPRESS T-LYMPHOCYTE; REFRACTORY ACUTE GVHD; PLATELET-RICH PLASMA; NATURAL-KILLER-CELLS;
D O I
10.1111/j.1423-0410.2009.01227.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mesenchymal Stem Cells/Multipotent Marrow Stromal Cells (MSC) are multipotent adult stem cells present in all tissues, as part of the perivascular population. As multipotent cells, MSCs can differentiate into different tissues originating from mesoderm ranging from bone and cartilage, to cardiac muscle. Conflicting data show that MSCs could be pluripotent and able to differentiate into tissues and cells of non-mesodermic origin as neurons or epithelial cells. Moreover, MSCs exhibit non-HLA restricted immunosuppressive properties. This wide range of properties leads to increasing uses of MSC for immunomodulation or tissue repair. Based on their immunosuppressive properties MSC are used particularly in the treatment of graft versus host disease, For tissue repair, MSCs can work by different ways from cell replacement to paracrine effects through the release of cytokines and to regulation of immune/inflammatory responses. In regenerative medicine, trials are in progress or planed for healing/repair of different tissue or organs as bone, cartilage, vessels, myocardium, or epithelia. Although it has been demonstrated that ex-vivo expansion processes using fetal bovine serum, recombinant growth factors (e.g. FGF2) or platelet lysate are feasible, definitive standards to produce clinical-grade MSC are still lacking. MSCs have to be produced according GMP and regulation constraints. For answering to the numerous challenges in this fast developing field of biology and medicine, integrative networks linking together research teams, cell therapy laboratories and clinical teams are needed.
引用
收藏
页码:93 / 107
页数:15
相关论文
共 138 条
  • [1] Human mesenchymal stem cells modulate allogeneic immune cell responses
    Aggarwal, S
    Pittenger, MF
    [J]. BLOOD, 2005, 105 (04) : 1815 - 1822
  • [2] Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
  • [3] Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth:: role of stromal cells in follicular lymphoma pathogenesis
    Ame-Thomas, Patricia
    Maby-El Hajjami, Helene
    Monvoisin, Celine
    Jean, Rachel
    Monnier, Delphine
    Caulet-Maugendre, Sylvie
    Guillaudeux, Thierry
    Lamy, Thierry
    Fest, Thierry
    Tarte, Karin
    [J]. BLOOD, 2007, 109 (02) : 693 - 702
  • [4] Neuronal Differentiation Potential of Human Adipose-Derived Mesenchymal Stem Cells
    Anghileri, Elena
    Marconi, Silvia
    Pignatelli, Angela
    Cifelli, Pierangelo
    Galie, Mirco
    Sbarbati, Andrea
    Krampera, Mauro
    Belluzzi, Ottorino
    Bonetti, Bruno
    [J]. STEM CELLS AND DEVELOPMENT, 2008, 17 (05) : 909 - 916
  • [5] Adipose-derived stem cells are a source for cell therapy of the corneal stroma
    Arnalich-Montiel, Francisco
    Pastor, Silvia
    Blazquez-Martinez, Alejandro
    Fernandez-Delgado, Jorge
    Nistal, Manuel
    Alio, Jorge L.
    De Miguel, Maria P.
    [J]. STEM CELLS, 2008, 26 (02) : 570 - 579
  • [6] Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation
    Ball, Lynne M.
    Bernardo, Maria Ester
    Roelofs, Helene
    Lankester, Arjan
    Cometa, Angela
    Egeler, R. Maarten
    Locatelli, Franco
    Fibbe, Willem E.
    [J]. BLOOD, 2007, 110 (07) : 2764 - 2767
  • [7] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
    Bartholomew, A
    Sturgeon, C
    Siatskas, M
    Ferrer, K
    McIntosh, K
    Patil, S
    Hardy, W
    Devine, S
    Ucker, D
    Deans, R
    Moseley, A
    Hoffman, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) : 42 - 48
  • [8] Reply to 'The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical study' by Ning et al.
    Behre, G.
    Theurich, S.
    Weber, T.
    Christopeit, M.
    [J]. LEUKEMIA, 2009, 23 (01) : 178 - 178
  • [9] Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment
    Bensidhoum, M
    Chapel, A
    Francois, S
    Demarquay, C
    Mazurier, C
    Fouillard, L
    Bouchet, S
    Bertho, JM
    Gourmelon, P
    Aigueperse, J
    Charbord, P
    Gorin, NC
    Thierry, D
    Lopez, M
    [J]. BLOOD, 2004, 103 (09) : 3313 - 3319
  • [10] Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term In vitro culture and do not exhibit telomere maintenance mechanisms
    Bernardo, Maria Ester
    Zaffaroni, Nadia
    Novara, Francesca
    Cometa, Angela Maria
    Avanzini, Maria Antonietta
    Moretta, Antonia
    Montagna, Daniela
    Maccario, Rita
    Villa, Raffaella
    Daidone, Maria Grazia
    Zuffardi, Orsetta
    Locatelli, Franco
    [J]. CANCER RESEARCH, 2007, 67 (19) : 9142 - 9149